TRAXENS
Traxens, a company that provides high-value data and services for the supply chain industry, announces today a major partnership with COSCO Shipping Logistics that aims to promote a full set of IoT data services based on Traxens cutting-edge smart container solutions. Both companies are carrying out a test program to provide IoT data services to COSCO Shipping Logistics’ large worldwide base of beneficial cargo owners (BCO) customers and aiming to join force in promoting supply chain digitalization. This follows the opening of Traxens’ China office – its first outside of France.
COSCO is a leading global shipping company and a container logistics operator in China. In partnering with COSCO, Traxens will be able to demonstrate its capacity in creating customer values through promoting its smart container solutions and digital services, and significantly contributing to the ongoing digitalization of the global container logistics industry. As the global supply chain becomes more and more competitive, improved tracking and smart data management is an increasingly important differentiation factor for all the major players in the shipping industry.
Through this partnership, COSCO will be able to offer premium data services to its large base of BCOs who are seeking door-to-door visibility and ever-increasing efficiency in their supply chains. This joint development in container supply chain digitalization marks a milestone in Traxens’ international expansion strategy and will help the company push forward with further business development in Asia.
“Our main focus as a business is to be able to create substantial customer value by delivering superior solution and services through technological innovation and global customer support capacity” said David Marchand, Traxens CEO. “Our partnership with COSCO will greatly benefit cargo owners and end-users and encourage further digitalization of the container logistics industry to the benefit of customers worldwide.”
“Traxens is delighted to be working with COSCO, providing its industry-proven smart container solutions to help streamline the company’s operations and enhance customers experience,” said Vincent Gu, managing director, Traxens Asia-Pacific. “Providing fleets with global visibility, exception management and business intelligence is what Traxens does best. By partnering up with global shipping companies such as COSCO we are able to demonstrate what our market-leading IoT solutions are capable of, giving client companies end-to-end shipment visibility and predictive insights that will benefit the end-users and the whole industry.”
“Through our partnership with Traxens, we aim to be at the forefront of digitalization and to maintain our leadership in the global container logistics industry ” said Sheng Liu, general manager of the container logistics division of COSCO SHIPPING Logistics. “As a leading global logistics company, we always pay close attention to the needs of our customers in their supply chain. We believe that the IoT services developed by Traxens are important to improve tracking and management of moving assets.”
About COSCO Shipping
COSCO SHIPPING Logistics Co., Ltd (COSCO SHIPPING Logistics), affiliated to CHINA COSCO SHIPPING CORPORATION LIMITED, is an international integrated logistics enterprise with shipping logistics as its core. It can provide modernized and professional whole-process logistics and supply chain solutions for customers at home and abroad. With a strong reputation and professional service capabilities, it is an important partner for governments, ports, railways, airports and large multinational companies.
The company, with headquarters in Beijing, is merged with CHINA COSCO Logistics Co., Ltd.(a part of COSCO Group), China Shipping Logistics Co., Ltd. (China Shipping Group) and China Shipping Agency Co., Ltd. (China Shipping Group). It was launched on December 21, 2016. China Ocean Shipping Tally Company was incorporated into COSCO SHIPPING Logistics after integration on September 18, 2017.
The company’s service network covers 30 provinces in China and many other countries and regions in Europe, America, Asia and Africa. There are over 600 sales and service points throughout the world; such broad sales and service networks provide customers with a full range of logistics solutions. Since its establishment, COSCO Shipping Logistics has won the Golden Pegasus Prize and has for many years been recognised as one of the National Advanced Logistics Enterprises.
http://www.cosco-logistics.com.cn/
About Traxens
Traxens drives digital transformation in the global supply chain. The company’s breakthrough IoT technology, data science expertise, global logistics experience and standards leadership unlock the value of real-time data generated from cargo assets shipped by sea, rail and road. Traxens is trusted by hundreds of global cargo owners, enabling them to reduce door-to-door transport costs, optimize their investments and minimize risk. By partnering with the world’s leading shipping lines, rail carriers and smart ports, Traxens helps all members of the global supply chain ecosystem improve decision making, operations and customer service. Traxens is privately held and headquartered in Marseille, France.
www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005361/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom